Literature DB >> 8285837

Drug-related pigmentation of the thyroid associated with papillary carcinoma.

G C Pastolero1, S L Asa.   

Abstract

Black pigmentation of the thyroid attributed to minocycline hydrochloride is known, but to our knowledge, pigmentation associated with antidepressants has not been reported. We studied four patients with papillary carcinoma associated with thyroid pigmentation; two had received minocycline therapy, and two had received long-term treatment with antidepressants. The thyroids of patients who had been treated with minocycline were black, with pigment primarily in nontumorous tissue. The thyroids associated with antidepressant therapy were dark red, with pigment in both tumorous and nontumorous tissue. All four cases were positive for periodic acid-Schiff, periodic acid-Schiff with diastase predigestion, and Schmorl's stains and negative for Prussian blue; the results differed from those found with Fontana's technique. Minocycline-related pigmentation appears to imply a role for the iodide peroxidase system in the accumulation of pigment, whereas pigmentation attributed to intake of antidepressants appears to result from lysosomal accumulation of the drug itself.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8285837

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  Follicular Carcinoma Associated with Minocycline-Induced Black Thyroid.

Authors:  Timothy A. Jennings; Christine E. Sheehan; Robert B. Chodos; James Figge
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

2.  Pathological changes in the thyroid gland in crush asphyxia.

Authors:  Roger W Byard
Journal:  Forensic Sci Med Pathol       Date:  2013-08-13       Impact factor: 2.007

3.  Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis.

Authors:  Christopher J Greene; Kristopher Attwood; Nitika J Sharma; Benjamin Balderman; Rongia Deng; Jason B Muhitch; Gary J Smith; Kenneth W Gross; Bo Xu; Eric C Kauffman
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.